Text Size

Targeted Screening for Taenia Solium Tapeworms

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Oregon Health and Science University.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborators:
San Marcos University School of Veterinary Medicine
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by:
Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT01296958
First received: February 15, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
  Purpose

The purpose of this study is to determine whether screening and treatment of tapeworm carriers can decrease community transmission of Taenia solium parasitic infection.


Condition Intervention
Tenia Solium Infection
 Drug: Niclosamide
Behavioral: Community education campaign

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Targeted Screening for Taenia Solium Tapeworms

Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • Porcine seroprevalence [ Time Frame: Every 4 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Intestinal tapeworm prevalence [ Time Frame: 16 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 1600
Study Start Date: March 2011
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Targeted screening
Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
 Drug: Niclosamide
Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
Active Comparator: Education
Community education about Taenia solium prevention.
 Behavioral: Community education campaign
Education about prevention of Taenia solium infection.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All community members are eligible

Exclusion Criteria:

  • Inability to provide informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01296958

Contacts
Contact: Seth E ONeal, MD MPH 5034948257 oneals@ohsu.edu

Locations
Peru
San Marcos University Not yet recruiting
Lima, Peru
Contact: Armando Gonzalez, DVM PhD     5114353189        
Principal Investigator: Armando Gonzalez, DVM PhD            
Sponsors and Collaborators
Oregon Health and Science University
San Marcos University School of Veterinary Medicine
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Seth E ONeal, MD MPH Oregon Health and Science University
Principal Investigator: Armando Gonzalez, DVM PhD San Marcos University School of Veterinary Medicine
  More Information

No publications provided

Responsible Party: Seth O'Neal / Assistant professor, Oregon Health & Science University
ClinicalTrials.gov Identifier: NCT01296958     History of Changes
Other Study ID Numbers: 1R21NS069275-01
Study First Received: February 15, 2011
Last Updated: February 15, 2011
Health Authority: United States: Institutional Review Board
Peru: Universidad Peruana Cayetano Heredia

Keywords provided by Oregon Health and Science University:
Taenia solium
cysticercosis
neurocysticercosis

Additional relevant MeSH terms:
Taeniasis
Cestode Infections
Helminthiasis
Parasitic Diseases
Niclosamide
Anticestodal Agents
Antiplatyhelmintic Agents
 Anthelmintics
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antinematodal Agents

ClinicalTrials.gov processed this record on May 19, 2013